Clinical trials: Newly Diagnosed
Leukemia
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00558519
- Testing
- cyclophosphamide, cytarabine, daunorubicin hydrochloride
- Volunteers
- 318 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Glioblastoma, Recurrent Gliosarcoma
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma
- Trial name
- NCT04477200
- Testing
- Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Pulmonary Tuberculosis
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 plus PA-824 plus Pyrazinamide plus Clofazimine, TMC207 plus PA-824 plus Pyrazinamide, TMC207 plus PA-824 plus…
- Trial name
- NC-003 (NCT01691534)
- Testing
- TMC207 (J), PA-824 (PA), pyrazinamide (Z)
- Where
- 2 sites in South Africa
- Volunteers
- 105 people
- Sponsor
- Global Alliance for TB Drug Development
Plasma Cell Myeloma
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant.
- Trial name
- NCT02880228
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00736450
- Testing
- oblimersen sodium, rituximab, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Nebraska
Multiple Myeloma
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone.
- Trial name
- NCT03290950
- Testing
- daratumumab, carfilzomib, lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment…
- Trial name
- NCT02843074
- Testing
- elotuzumab, Lenalidomide, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- SCRI Development Innovations, LLC
Leukemia
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00096018
- Testing
- fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma of the Head and Neck
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This study is conducted in Japanese newly diagnosed locally advanced SCCHN patients in order to assess tolerability and feasibility of Cetuximab plus concomitant boost radiotherapy (RT) regimen (the study treatment) and its…
- Trial name
- NCT00865098
- Testing
- Cetuximab
- Where
- 4 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Central Nervous System Lymphoma
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
This is a multicenter open label randomized phase II trial. Enrolled Primary Central Nervous System Lymphoma (PCNSL) patients will be stratified according to the IELSG score and randomized to receive one of the follows as primary…
- Trial name
- NCT01011920
- Testing
- Methotrexate, Ara-C, Rituximab
- Where
- 54 sites in Denmark, Germany and 3 more
- Volunteers
- 227 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Glioma, Malignant, Surgery
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures.
- Conditions
- Glioma, Malignant, Surgery, Seizures
- Trial name
- NCT04497142
- Testing
- Perampanel, Standard of Care
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
This research study is evaluating a combination of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple myeloma.
- Trial name
- NCT02441686
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Graft vs Host Disease
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, enable a more rapid and effective steroid taper.
- Trial name
- NCT00350545
- Testing
- Rituximab, Prednisone, Cyclosporine A
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Lymphoma
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00376961
- Testing
- rituximab, bortezomib, cyclophosphamide
- Where
- 147 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Tuberculosis
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
The purpose of this study is to determine the mycobactericidal activity of combinations of bedaquiline (J), moxifloxacin (M), PA-824 (Pa) and pyrazinamide (Z) regimens during 8 weeks of treatment.
- Trial name
- NC-005 (NCT02193776)
- Testing
- PA-824, bedaquiline, moxifloxacin
- Where
- 10 sites in South Africa, Tanzania and 1 more
- Volunteers
- 240 people
- Sponsor
- Global Alliance for TB Drug Development
Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer.
- Conditions
- Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Trial name
- NCT02883062
- Testing
- Atezolizumab, Biospecimen Collection, Carboplatin
- Where
- 14 sites in United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
The purpose of this study is to find out whether Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given with a targeted agent, bevacizumab, and how…
- Trial name
- NCT01209442
- Testing
- Bevacizumab, Temozolomide, RT (Radiation Therapy)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Ganglioneuroblastoma, Stage 1 Neuroblastoma
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread.
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma
- Trial name
- NCT01798004
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin
- Where
- 123 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Stage I Endometrial Carcinoma, Stage II Endometrial Carcinoma
Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
This clinical trial studies lymph node mapping in patients with newly diagnosed endometrial cancer undergoing surgery. Lymph node mapping may help in planning surgery to remove endometrial cancer and affected lymph nodes.
- Conditions
- Stage I Endometrial Carcinoma, Stage II Endometrial Carcinoma, Stage III Endometrial Carcinoma, Stage IV Endometrial Carcinoma
- Trial name
- NCT01939028
- Testing
- lymph node mapping, sentinel lymph node biopsy, isosulfan blue
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center